MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.88% | 14.31% | 12.56% | 24.86% | 30.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.88% | 14.31% | 12.56% | 24.86% | 30.89% |
| Cost of Revenue | 26.62% | 30.12% | 12.34% | 23.91% | 4.09% |
| Gross Profit | -5.34% | -8.41% | 12.99% | 26.88% | 135.10% |
| SG&A Expenses | -4.13% | -3.53% | -17.14% | 3.40% | -9.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -236.23% | 8.65% | -174.77% | -123.11% | -39.70% |
| Total Operating Expenses | 11.40% | 13.48% | -2.45% | 13.21% | -2.85% |
| Operating Income | 7.56% | -8.65% | 50.45% | 21.53% | 59.62% |
| Income Before Tax | 34.65% | 37.66% | 47.34% | 20.92% | 24.96% |
| Income Tax Expenses | -- | -- | -- | -- | -2,940.91% |
| Earnings from Continuing Operations | 33.14% | 36.37% | 46.28% | 19.27% | 26.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.14% | 36.37% | 46.28% | 19.27% | 26.62% |
| EBIT | 7.56% | -8.65% | 50.45% | 21.53% | 59.62% |
| EBITDA | -8.28% | -39.30% | 59.56% | 29.13% | 70.83% |
| EPS Basic | 35.65% | 39.11% | 48.44% | 29.41% | 39.66% |
| Normalized Basic EPS | 9.09% | -5.48% | 53.68% | 32.17% | 68.05% |
| EPS Diluted | 35.65% | 39.11% | 48.44% | 29.41% | 39.66% |
| Normalized Diluted EPS | 9.09% | -5.48% | 53.68% | 32.17% | 68.05% |
| Average Basic Shares Outstanding | 4.12% | 4.33% | 4.76% | 13.18% | 17.57% |
| Average Diluted Shares Outstanding | 4.12% | 4.33% | 4.76% | 13.18% | 17.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |